secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-07-02T20:23:41+00:00
Accession:  0001140361-26-027445
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio raises $1B in convertible preferred equity from Sixth Street and KKR
------------------------------------------------------------------------------

- Sixth Street invested $800M and HCRx (KKR affiliate) invested $133.9M in Series A convertible preferred stock.
- Initial conversion price of $137.79 per share (over 100% premium to 30-day VWAP); increases to $153.10 after year 5.
- Preferred stock carries 7.00% annual dividend, payable in kind or cash at Company's option; no scheduled maturity.
- Proceeds to accelerate launches of Attruby, BBP-418, encaleret, and infigratinib over next 12 months.
- Company may redeem after year 3 at escalating premiums; conversion mandatory if stock price exceeds 200% of conversion price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/0001140361-26-027445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/ef20077282_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-027445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer